Lung function and health-related quality of life among adult patients following pulmonary TB treatment
The International Journal of Tuberculosis and Lung Disease · 2024
DOI: 10.5588/ijtld.24.0029 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, 2024. Verfasst von J Zawedde und 14 weiteren Autor:innen. Beteiligte Einrichtung: Makerere University School of Public Health, Kampala, Infectious Diseases Research Collaboration, Kampala, Uganda. Hauptthemen laut MEDLINE: Quality of Life, Tuberculosis, Pulmonary, Spirometry. Die Arbeit wurde bisher 25-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: FIC NIH HHS, NIAID NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
OBJECTIVES
Pulmonary TB (PTB) increases the risk of chronic lung complications, which are associated with increased morbidity and mortality. We determined the prevalence and predictors of post-TB lung disease and persistent symptoms in a resource-limited setting.
METHODS
Adults who completed PTB treatment underwent spirometry and completed the St. George’s Respiratory Questionnaire (SGRQ), a questionnaire that assesses quality of life on symptom, activity, and impact. We performed multivariate analyses to calculate the X-adjusted prevalence ratio (PR adj ) of abnormal spirometry and identify associated risk factors.
RESULTS
Among the 162 participants, 89 (54.9%) were male. The median age was 32 years, and 65 (40.1%) had HIV. Overall, 65 participants (40.1%) had abnormal lung function, with spirometric restriction seen in 29.0%, obstruction in 4.9%, and a mixed pattern in 6.2%. Smoking (PR adj 1.88, 95% CI 1.11–3.16; P = 0.02) and female sex (PR adj 1.81, 95% Cl 1.15–2.84; P = 0.01) were independent risk factors for abnormal lung function. The median SGRQ scores were higher in participants with cavitation ( P < 0.001) or bilateral consolidation on initial chest X-ray ( P = 0.01).
CONCLUSIONS
Lung function abnormalities, particularly spirometric restriction, are common in patients completing PTB treatment. Female sex and smoking status were associated with lung function abnormalities; therefore, additional studies to understand the underlying mechanistic pathways are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Makerere University School of Public Health, Kampala, Infectious Diseases Research Collaboration, Kampala, Uganda.
- Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, CA.
- Infectious Diseases Research Collaboration, Kampala, Uganda.
- Makerere University School of Public Health, Kampala.
- Department of Anesthesia, San Francisco General Hospital, San Francisco, CA, USA.
- Makerere University College of Health Sciences; Kampala, Uganda.
Förderung
- FIC NIH HHS
- NIAID NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Zawedde, J., Abelman, R., Musisi, E., Nyabigambo, A., Sanyu, I., Kaswabuli, S., Byanyima, P., Lewis, E., Sessolo, A., Lalitha, R., Kiwanuka, N., Crothers, K., Worodria, W., Davis, J. L., & Huang, L. (2024). Lung function and health-related quality of life among adult patients following pulmonary TB treatment. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.24.0029
Vancouver
Zawedde J, Abelman R, Musisi E, Nyabigambo A, Sanyu I, Kaswabuli S, et al. Lung function and health-related quality of life among adult patients following pulmonary TB treatment. The International Journal of Tuberculosis and Lung Disease. 2024. doi:10.5588/ijtld.24.0029
BibTeX
@article{Zawedde2024,
author = {Zawedde, J and Abelman, R and Musisi, E and Nyabigambo, A and Sanyu, I and Kaswabuli, S and Byanyima, P and Lewis, E and Sessolo, A and Lalitha, R and Kiwanuka, N and Crothers, K and Worodria, W and Davis, J L and Huang, L},
title = {Lung function and health-related quality of life among adult patients following pulmonary TB treatment},
journal = {The International Journal of Tuberculosis and Lung Disease},
year = {2024},
doi = {10.5588/ijtld.24.0029}
}
EUVIMED